ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Renovaro Inc

Renovaro Inc (RENB)

1.64
0.19
(13.10%)
Closed June 14 4:00PM
1.54
-0.10
(-6.10%)
After Hours: 7:56PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
1.54
Bid
1.52
Ask
1.57
Volume
735,800
1.445 Day's Range 1.65
0.6601 52 Week Range 5.25
Market Cap
Previous Close
1.45
Open
1.46
Last Trade Time
Financial Volume
$ 1,138,460
VWAP
1.5472
Average Volume (3m)
582,693
Shares Outstanding
143,668,372
Dividend Yield
-
PE Ratio
-2.61
Earnings Per Share (EPS)
-0.28
Revenue
-
Net Profit
-39.68M

About Renovaro Inc

Renovaro Biosciences Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer. The company's product pipeline includes ENOB-HV... Renovaro Biosciences Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer. The company's product pipeline includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a gene therapy curative treatment for HBV. It develops ENOB-DC-11, an allogeneic dendritic cell therapeutic vaccine for solid tumors; ENOB-DC-12-XX, allogeneic dendritic cell therapeutic vaccine for other solid tumors; and ENOB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. Enochian Biosciences, Inc. has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Enochian Biosciences, Inc. and changed its name to Renovaro Biosciences Inc. in August 2023. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Renovaro Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RENB. The last closing price for Renovaro was $1.45. Over the last year, Renovaro shares have traded in a share price range of $ 0.6601 to $ 5.25.

Renovaro currently has 143,668,372 shares outstanding. The market capitalization of Renovaro is $103.44 million. Renovaro has a price to earnings ratio (PE ratio) of -2.61.

RENB Latest News

Renovaro, Inc. Announces $10 million in Equity Committed

LOS ANGELES, June 14, 2024 (GLOBE NEWSWIRE) -- Renovaro, Inc. (NASDAQ: RENB) (the “Company”) announces that it has $10 million in additional equity committed at a price per share of $1.4726 and...

Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy

LOS ANGELES and AMSTERDAM, May 24, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB) and the Amsterdam UMC Cancer Center today announced an intended partnership and therefore signed an MoU...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.214.92537313431.342.341.2827515811.47836102CS
40.6369.23076923080.912.340.8712297691.42226913CS
12-1.32-46.15384615382.863.240.825826931.56542464CS
26-1.79-53.75375375383.335.250.824179612.12510312CS
520.6777.01149425290.875.250.66015125802.08934335CS
1560.6777.01149425290.875.250.66015125802.08934335CS
2600.6777.01149425290.875.250.66015125802.08934335CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
KAVLKaival Brands Innovations Group Inc
$ 5.96
(338.24%)
70.98M
LRHCLa Rosa Holdings Corporation
$ 1.165
(90.61%)
40.6M
SVMHSRIVARU Holding Ltd
$ 0.227586
(49.24%)
275.98M
BRFHBarfresh Food Group Inc
$ 3.03
(38.36%)
247.31k
NNENano Nuclear Energy Inc
$ 9.37
(32.53%)
1.77M
NXLNexalin Technologies Inc
$ 0.89
(-35.52%)
3.93M
INABIN8bio Inc
$ 1.095
(-34.82%)
4.92M
QXOQXO Inc
$ 134.10
(-34.71%)
142.22k
GANXGain Therapeutics Inc
$ 1.24
(-34.39%)
3.09M
KYTXKyverna Therapeutics Inc
$ 9.52
(-34.07%)
4.31M
NVDANVIDIA Corporation
$ 131.88
(1.75%)
309.29M
SVMHSRIVARU Holding Ltd
$ 0.227586
(49.24%)
275.98M
KITTNauticus Robotics Inc
$ 0.1921
(19.69%)
165.81M
CRKNCrown Electrokinetics Corporation
$ 0.0582
(-21.35%)
136.61M
SQQQProShares UltraPro Short QQQ
$ 8.43
(-1.29%)
112.45M

RENB Discussion

View Posts
jedijazz jedijazz 13 hours ago
$RENB News! Renovaro, Inc. Announces $10 million in Equity Committed
Renovaro Inc
Fri, Jun 14, 2024, 9:06 AM EDT

In this article:
RENB
+1.40%
Renovaro Inc

LOS ANGELES, June 14, 2024 (GLOBE NEWSWIRE) -- Renovaro, Inc. (NASDAQ: RENB) (the “Company”) announces that it has $10 million in additional equity committed at a price per share of $1.4726 and 10 percent warrant coverage.

“We appreciate confidence in the Company demonstrated by the investors,” said the Hon. Mark Dybul, MD, CEO. “We believe this is only the beginning. We are hopeful to be able to secure additional financing such as, but not limited to, long-term loans, grants and subsidies from various US and European institutions for which the Company is eligible – potentially worth tens of millions of dollars.”

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For media inquiries, please contact: karen@renovarocube.com

Source: Renovaro Inc.
👍️ 2 💪 2 💯 1 😍 1
jedijazz jedijazz 2 days ago
$RENB - Renovaro Inc. (NASDAQ: RENB) Aims To Revolutionize Cancer Detection And Treatment Using Multi-Cancer Detection Model With Nvidia AI Chips For Leadership In Early Detection - NVIDIA (NASDAQ:NVDA)

https://www.benzinga.com/partner/biotech/24/05/38641138/renovaro-inc-nasdaq-renb-aims-to-revolutionize-cancer-detection-and-treatment-using-multi-cancer- Benzinga #Healthcare #Biopharma $NVDA #AI #Computing #Power
👍️ 2 💪 2 💯 1 😍 1
ProfitScout ProfitScout 3 days ago
Impressive Short Squeeze Triggered for Cancer Immunotherapy Company Renovaro, Inc. (NASDAQ: RENB)
Click here:
https://markets.financialcontent.com/startribune/article/getnews-2024-6-10-impressive-short-squeeze-triggered-for-cancer-immunotherapy-company-renovaro-inc-nasdaq-renb
👍️ 1 🙂 1
glenn1919 glenn1919 4 days ago
RENB...........................https://stockcharts.com/h-sc/ui?s=RENB&p=W&b=5&g=0&id=p86431144783
👍️0
jedijazz jedijazz 4 days ago
$RENB $1.66 +28.29% HOD $2.34 (Nasdaq) Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy https://seekingalpha.com/pr/19737436-renovaro-inc-and-amsterdam-umc-cancer-center-poised-to-advance-cancer-immunotherapy?source=content_type%3Areact%7Csection%3APress%20Releases%7Csection_asset%3APress%20Releases%7Cfirst_level_url%3Asymbol%7Cbutton%3ATitle%7Clock_status%3ANo%7Cline%3A1
👍️ 1 💪 1 💯 1 😍 1
tw0122 tw0122 5 days ago
Still going 2.34 + 50% hod
👍️0
jedijazz jedijazz 1 week ago
$RENB Renovaro, Amsterdam UMC Cancer Center Plan to Form Joint Venture for Cancer Immunotherapy https://www.marketscreener.com/quote/stock/RENOVARO-INC-47536345/news/Renovaro-Amsterdam-UMC-Cancer-Center-Plan-to-Form-Joint-Venture-for-Cancer-Immunotherapy-46820158/ @Nasdaq @Marketscreener1 #collaboration
👍️ 1 💪 1 💯 1
jedijazz jedijazz 1 week ago
$RENB $1.34 HOD $1.47 #Nasdaq Market Outlook #Bullish- BUY. The last pattern detected was #bullish with positive implications. The overall evidence is very high that there will be signal for a STRONG BUY soon.

👍️ 1 💪 1 💯 1 😍 1
jedijazz jedijazz 1 week ago
$RENB At GEDiCube/ RenovaroCube, we are committed to the early detection of cancer, to intervene at a stage where treatment can be most effective. We have developed an award-winning AI Technology that significantly accelerates early cancer detection and diagnosis https://compasslivemedia.com/renb/
👍️ 1 💯 1 😍 1
jedijazz jedijazz 2 weeks ago
$RENB #informative #newsfeed #scientific #cancer #immunotherapy #studies#Nadaq Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy!
$RENB #Undervalued https://www.tipranks.com/news/the-fly/renovaro-biosciences-amsterdam-umc-cancer-center-announce-intended-partnership
👍️ 1 😍 1
jedijazz jedijazz 2 weeks ago
$RENB $1.50 +2.04% Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy #MarketScreener https://www.marketscreener.com/quote/stock/RENOVARO-INC-47536345/news/Renovaro-Inc-and-Amsterdam-UMC-Cancer-Center-Poised-to-Advance-Cancer-Immunotherapy-46818916/?utm_source=twitter&utm_medium=social&utm_campaign=share #Gedicube #Renovaro
👍️ 1 💯 1 😍 1
jedijazz jedijazz 3 weeks ago
$RENB Advancing Cancer Immunotherapy in Collaboration with Amsterdam UMC Cancer Center; Creating a “NEWCO”: Nasdaq: RENB

$RENB uses $NVDA World Class AI Chips and Computing Power in their advancement of Early Cancer Diagnostics

Renovaro Biosciences Inc (NASDAQ:RENB) with a dedicated team of researchers collaborating closely with experts from both RenovaroBio and the Amsterdam UMC Cancer Center and will benefit from the combined resources, expertise, and extensive”— The Hon. Mark Dybul, MD, CEOLOS ANGELES,, CALIFORNIA, UNITED STATES, May 24, 2024 /EINPresswire.com/ -- Advancing Cancer Immunotherapy in Collaboration with Amsterdam UMC Cancer Center; Creating a “NEWCO”: Renovaro, Inc. (Nasdaq: RENB)

$RENB uses $NVDA World Class AI Chips and Computing Power in their advancement of Early Cancer Diagnostics

For more information on this Exciting NASDAQ Company: RENB visit: http://www.renovarobio.com and https://compasslivemedia.com/renb/

* Focus on Personalized Medicine for Longevity Powered by Mutually Reinforcing AI and Biotechnology Platforms.

* Plans to Acquire 100% of Cyclomics for Shared Commitment to Advancing State-of-the-Art Technologies in Cancer Diagnostics and Treatment.

* Relationships with Oxford Nanopore & Nvidia position RENB as a Leader in Early Cancer Diagnostics and Monitoring Treatment Efficacy.

* Introduced Flamingo, a Potentially Groundbreaking Multi-Cancer Detection Model to Transform Early Cancer Diagnostics.

Breaking News:
RENB and the Amsterdam UMC Cancer Center today announced an intended partnership and therefore signed an MoU to establish a joint company based in the Netherlands aimed at pioneering the next generation of personalized cancer immunotherapy. Both Renovaro and Amsterdam UMC emphasize the need to carry out the appropriate corporate and scientific due diligence before taking these next steps. Alongside the independent validation, any final contractual commitments are subject to approval from both executive boards.

This collaboration would bring together Renovaro's proprietary cancer vaccine technology and the Cancer Center's expertise in several ancillary immunomodulatory technologies, toward innovative advancements in cancer treatment.

The proposed “Newco” will be headquartered in Amsterdam, The Netherlands. By merging Renovaro's cutting-edge vaccine technology with the Cancer Center's expertise, the aim is to develop personalized cancer immunotherapy solutions tailored to individual patients, overcoming immunotherapy resistance.

This new venture will operate independently, with a dedicated team of researchers collaborating closely with experts from both RenovaroBio and the Amsterdam UMC Cancer Center, and will benefit from the combined resources, expertise, and extensive networks of its parent organizations, ensuring a strong foundation for success.

Both Renovaro and the Amsterdam UMC Cancer Center believe that the commitment to driving innovation in more non-invasive cancer therapies will enable significant strides in the fight against cancer, offering hope to patients worldwide.

Renovaro, Inc (Nasdaq: RENB) aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. RENB includes Renovaro Bio with its advanced cell-gene immunotherapy company and RenovaroCube. RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 10-year history. RENB brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.

Upon the closing of the acquisition of Cyclomics (winner of the Health Holland Venture Challenge), RenovaroCube will be capable of performing liquid biopsies using proprietary technologies to identify single cancer DNA molecules in only one vial of blood. In combination with Oxford Nanopore Technology, genetic information can be retrieved over multiple genetic layers to develop the next generation of cancer diagnostics. This has the potential to transform cancer care by enabling faster and more accurate diagnosis throughout the patient journey.

RENB has announced a significant milestone in their collaboration. RenovaroCube has entered into an amendment to its binding letter of intent to acquire 100% ownership of Cyclomics, further cementing their shared commitment to advancing state-of-the-art technologies in cancer diagnostics and treatment. Their combined relationships with Oxford Nanopore and Nvidia will further position RENB RenovaroCube to be a leader in early cancer diagnostics and monitoring of treatment efficacy. Oxford Nanopore is a leader in sequencing technologies and Nvidia will provide vital supercomputing power and front-edge software solutions such as Parabricks, BioNeMo, Monai, and Nemo.

Initially set at a 75% acquisition, this decision to acquire the remaining 25% of Cyclomics reflects the resounding success of their partnership and the remarkable synergy between the two companies. Upon closing, RENB believes the acquisition of Cyclomics into the Renovaro family will further strengthen its ability to create a powerhouse for cancer diagnostics throughout the entire patient journey, from early detection/recurrence and personalized treatment in late-stage disease

Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a Novel AI Model Based on Fragmentomics

On April 30th RENB unveiled its Flamingo, a potentially groundbreaking multi-cancer detection model contributing to its mission to transform early cancer diagnostics. Leveraging ultra-low pass whole genome sequencing (ULP-WGS) of cell-free DNA (cfDNA), Flamingo represents a promising leap forward in the fight against cancer.

Traditional cancer detection methods often fall short in identifying cancers at an early stage when treatment is the most effective. However, the RENB Flamingo has the potential to overcome these limitations by harnessing the power of AI to analyze minute amounts of cfDNA data that is highly accurate.

"At RenovaroCube, we believe in pushing the boundaries of possibility," states Daan Vessies, senior scientist at RenovaroCube. "Flamingo underscores our commitment to change cancer diagnostics in a transformative way, ultimately offering clinicians a powerful tool to detect cancer across diverse omic layers."

RENB believes that no single model or molecular modality will reach the requisite sensitivity and specificity throughout the entire patient journey for personalized, precision medicine, from early detection to predicting the effectiveness of various treatment options, to monitoring the response to therapy within days of starting it, to detecting recurrence at the earliest possible moment. Therefore, our AI/machine learning platform, The RENB Cube, integrates multi-omic data, offering a uniquely comprehensive approach to cancer detection by leveraging a library of trained models for multiple omic layers. One such model Flamingo focuses on is the detection of cancer from ultra-low pass whole genome sequencing (ULP-WGS) cfDNA data using fragmentomics.

The RENB Flamingo's development marks a significant milestone in the quest for early cancer detection with RenovaroCube’s engine. By utilizing as few as only 200,000 cell-free DNA fragments per sample, integrating fragment lengths, and sequence motifs, and employing a meticulously designed neural network, Flamingo achieves remarkable performance in distinguishing cancer from healthy samples.

By augmenting The RENB Cube's arsenal of models operating across various omic layers, Flamingo contributes to the development of non-invasive diagnostics to detect cancer early, enabling timely interventions and improving patient outcomes.

RENB RenovaroCube invites interested doctors and scientists from international research institutions, clinical cancer centers, and all stakeholders to join in the early research use application of our AI/machine learning platform to advance cancer diagnostics and pave the way for a healthier future.

RENB Combined Companies aim to Disrupt Cancer Diagnosis and treatment through early disease and recurrence detection, prediction of response to treatment, and personalized therapy.
👍️ 1 💯 1 😍 1
glenn1919 glenn1919 3 weeks ago
RENB.............................................https://stockcharts.com/h-sc/ui?s=RENB&p=W&b=5&g=0&id=p86431144783
👍️0
ProfitScout ProfitScout 3 weeks ago
$RENB News: Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy

LOS ANGELES and AMSTERDAM, May 24, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB) and the Amsterdam UMC Cancer Center today announced an intended partnership and therefore signed an MoU to establish a joint company based in the Netherlands aimed at pioneering the next generation of personalized cancer immunotherapy. Both Renovaro and Amsterdam UMC emphasize the need to carry out the appropriate corporate and scientific due diligence before taking these next steps. Alongside the independent validation any final contractual commitments are subject to approval from both executive boards.

This collaboration would bring together Renovaro's proprietary cancer vaccine technology and the Cancer Center's expertise in several ancillary immunomodulatory technologies, towards innovative advancements in cancer treatment.

The proposed “Newco” will be headquartered in Amsterdam, The Netherlands. By merging Renovaro's cutting-edge vaccine technology with the Cancer Center's expertise, the aim is to develop personalized cancer immunotherapy solutions tailored to individual patients, overcoming immunotherapy resistance.

"We believe that by combining our expertise in cancer research and therapy with Renovaro's innovative allogenic dendritic vaccine technology, we can accelerate the development of personalized cancer treatments," said Prof. Geert Kazemier, Director of the Amsterdam UMC Cancer Center. "This once again represents our commitment to advancing cancer immunotherapy and improving patient outcomes."

"We are thrilled to partner with the Amsterdam UMC Cancer Center to drive innovation in cancer immunotherapy," said Coenraad K. van Kalken MD PhD, Director of RenovaroCube. "This collaboration represents a recognition of our potentially transformative technologies and a strategic alignment of our shared vision to change cancer treatment through personalized medicine. Also, as part of the MoU certain clinical activities would be moved to Amsterdam."

This new venture will operate independently, with a dedicated team of researchers collaborating closely with experts from both RenovaroBio and the Amsterdam UMC Cancer Center and will benefit from the combined resources, expertise, and extensive networks of its parent organizations, ensuring a strong foundation for success.

Both Renovaro and the Amsterdam UMC Cancer Center believe that the commitment to driving innovation in more non-invasive cancer therapies will enable significant strides in the fight against cancer, offering hope to patients worldwide.

About Renovaro Group:

Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube. RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.

Upon the closing of the previously announced acquisition of Cyclomics (winner of the Health Holland Venture Challenge), RenovaroCube will be capable of performing liquid biopsies using proprietary technologies to identify single cancer DNA molecules in only one vial of blood. In combination with Oxford Nanopore Technology, genetic information can be retrieved over multiple genetic layers to develop the next generation of cancer diagnostics. We believe this will transform cancer care by enabling faster and more accurate diagnosis throughout the patient journey.

About Amsterdam UMC/ CCA

With over 16,000 employees and 1,400 beds, Amsterdam UMC is one of the largest University Hospitals in the Benelux. The two locations of Amsterdam UMC, merged in 2020, work together to provide good and accessible care for millions of people. Amsterdam UMC focuses on a future where diseases can be prevented and where patients receive the best treatments. Amsterdam UMC has eight research institutes, the largest being the Cancer Center. The VUmc location (former Free University Hospital) emphasizes cancer and neurodegenerative disease research. The researchers affiliated are internationally recognized among the top in medical scientific research.

The Cancer Center Amsterdam was founded as a research institute over 25 years ago by Prof. Bob Pinedo and his colleagues to pursue innovative cancer research. Today, Cancer Center Amsterdam has become much more than an academic oncology center, encompassing all cancer care, research, and education at Amsterdam UMC. It is also aligned with the Cancer Center Amsterdam Foundation, which raises funds to empower promising developments in oncology research and patient care at Amsterdam UMC, and with Amsterdam UMC Holding, the corporate entity set up to actively bring highly promising medical innovation to the market.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For media inquiries, please contact: karen@renovarocube.com

Source: Renovaro Inc.

https://www.globenewswire.com/newsroom/ti?nf=OTEyMzQ1MyM2MjY4MjU3IzIxMjA2Nzk=
https://ml.globenewswire.com/media/NmVlM2U4YTItMmZkMi00OGY5LTkzNzAtODVkZjA3Y2Y0YjE5LTExMzIyNTA=/tiny/Renovaro-Inc.png

Source: Renovaro Inc
👍️ 1 🙂 1
jedijazz jedijazz 3 weeks ago
$RENB 1.44 +53.19% Finally seeing that bullish move on so much great news and promise by the company. SO many reasons to have RENB on radar, Thank you!

$RENB Discover more with @renovaro @Nasdaq https://t.co/hugpNhp4V9 Top Ten Reasons to Have $RENB on your radar! pic.twitter.com/mznQvlGeqv— 🔥🔥🌐UltimateTraderX🌐🔥🔥 (@JediJazz22) April 8, 2024
👍️ 1
jedijazz jedijazz 3 weeks ago
$RENB - Renovaro Inc. (NASDAQ: RENB) Treatment Using Multi-Cancer Detection Model With Nvidia AI Chips For Leadership In Early Detection - NVIDIA (NASDAQ:NVDA)

https://www.benzinga.com/partner/biotech/24/05/38641138/renovaro-inc-nasdaq-renb-aims-to-revolutionize-cancer-detection-and-treatment-using-multi-cancer- Benzinga #Healthcare #Biopharma #AI #Computing #Power
👍️ 1 💯 1 😍 1
jedijazz jedijazz 1 month ago
$RENB -Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics https://finance.yahoo.com/news/transforming-cancer-detection-renovarocube-introduces-150000564.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via
@YahooFinance
👍️ 1 💪 1 💯 1 😍 1
jedijazz jedijazz 1 month ago
$RENB - Renovaro Inc. (NASDAQ: RENB) Aims To Revolutionize Cancer Detection And Treatment Using Multi-Cancer Detection Model With Nvidia AI Chips For Leadership In Early Detection - NVIDIA (NASDAQ:NVDA)
https://www.benzinga.com/partner/biotech/24/05/38641138/renovaro-inc-nasdaq-renb-aims-to-revolutionize-cancer-detection-and-treatment-using-multi-cancer- #Benzinga #Healthcare #Biopharma #Cancersucks $NVDA #AI #Computing #Power
👍️ 1 💪 1 😍 1
jedijazz jedijazz 1 month ago
$RENB Buy Opinion. Renovaro Inc. (NASDAQ: RENB) Aims To Revolutionize Cancer Detection And Treatment Using Multi-Cancer Detection Model With Nvidia AI Chips For Leadership In Early Detection #Bullish https://www.benzinga.com/partner/biotech/24/05/38641138/renovaro-inc-nasdaq-renb-aims-to-revolutionize-cancer-detection-and-treatment-using-multi-cancer-
👍️ 1 💪 1 💯 1 😍 1
jedijazz jedijazz 1 month ago
$RENB Renovaro, Inc. (Nasdaq: RENB), a company at the forefront of AI-driven healthcare innovation, proudly unveils Flamingo, a potentially groundbreaking multi-cancer detection model https://finance.yahoo.com/news/transforming-cancer-detection-renovarocube-introduces-150000564.html
👍️ 2 💪 2 💯 1
Stengaard_dk Stengaard_dk 1 month ago
It's been an interesting month - Renovaro has focused on completing the Cyclomics deal. The deal has been altered from LOI of 75% to ownership of 100%, and so far so good.
The market has been focused on Russell2000, and whether or not Renovaro made the threshold. Marketcap cut-off was around 140 mio USD, so it looks as if RENOVARO passed the exam easy-peasy. I must admit that as a shareholder it didn't quite feel that way - when the stock traded at 1.30 I was worried sick .
But the Ranking day is one thing - reconstitution end of June is another.
So right now the company MUST be focused on funding, and in the meantime, short-sellers are doing their best to make that a nightmare for existing shareholders. I hope that whoever ends up buying in to Renoovaro pays more than the present "hammered" price - but time will tell
👍️0
jedijazz jedijazz 1 month ago
$RENB $1.525 HOD $1.58 RENOVARO IS TRANSFORMING CANCER DETECTION: RENOVAROCUBE INTRODUCES FLAMINGO, A NOVEL #AI MODEL BASED ON FRAGMENTOMICS https://renovarobio.com/news/transforming-cancer-detection-renovarocube-introduces-flamingo-a-novel-ai-model-based-on-fragmentomics/
👍️ 1 💯 1 😍 1
jedijazz jedijazz 1 month ago
$RENB Great Volume early! Headed for another huge day.
👍️ 1 💪 1 💯 1 😍 1
jedijazz jedijazz 1 month ago
$RENB Closed Higher on NEWS! Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel #AI model based on Fragmentomics https://finance.yahoo.com/news/transforming-cancer-detection-renovarocube-introduces-150000564.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
@YahooFinance
#RenovaroInc
@Nasdaq
#AI #News #Healthcare #CancerDetection #Cancer #FDA
👍️ 1 💪 1 💯 1 😍 1
jedijazz jedijazz 1 month ago
$RENB 1.695 +8.65% on NEWS - RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics ; Transforming Cancer Detection https://finance.yahoo.com/news/transforming-cancer-detection-renovarocube-introduces-150000564.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
👍️ 1 💥 1 💯 1 😍 1 🚀 1
ProfitScout ProfitScout 1 month ago
$RENB News: Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics

LOS ANGELES and AMSTERDAM, April 30, 2024 (GLOBE NEWSWIRE) -- RenovaroCube, wholly owned subsidiary of Renovaro, Inc. (Nasdaq: RENB), a company at the forefront of AI-driven healthcare innovation, proudly unveils Flamingo, a potentially groundbreaking multi-cancer detection model contributing to its mission to transform early cancer diagnostics. Leveraging ultra-low pass whole genome sequencing (ULP-WGS) of cell-free DNA (cfDNA), Flamingo represents a promising leap forward in the fight against cancer.

Traditional cancer detection methods often fall short in identifying cancers at an early stage when treatment is the most effective. However, Flamingo has the potential to overcome these limitations by harnessing the power of AI to analyze minute amounts of cfDNA data that is highly accurate.

"At RenovaroCube, we believe in pushing the boundaries of possibility," states Daan Vessies, senior scientist at RenovaroCube. "Flamingo undescores our commitment to change cancer diagnostics in a transformative way, ultimately offering clinicians a powerful tool to detect cancer across diverse omic layers."

The Company believes that no single model or molecular modality will reach the requisite sensitivity and specificity throughout the entire patient journey for personalized, precision medicine, from early detection, to predicting the effectiveness of various treatment options, to monitoring the response to therapy within days of starting it, to detecting recurrence at the earliest possible moment. Therefore, our AI/machine learning platform, The Cube, integrates multi-omic data, offering a uniquely comprehensive approach to cancer detection by leveraging a library of trained models for multiple omic layers. One such model Flamingo focuses on is the detection of cancer from ultra-low pass whole genome sequencing (ULP-WGS) cfDNA data using fragmentomics.

Flamingo's development marks a significant milestone in the quest for early cancer detection with RenovaroCube’s engine. By utilizing as few as only 200,000 cell-free DNA fragments per sample, integrating fragment lengths, sequence motifs and employing a meticulously designed neural network, Flamingo achieves remarkable performance in distinguishing cancer from healthy samples.

By augmenting The Cube's arsenal of models operating across various omic layers, Flamingo contributes to the development of non-invasive diagnostics to detect cancer early, enabling timely interventions and improving patient outcomes.

"Adding Flamingo to our Cube will accelerate our efforts to realize a paradigm shift in cancer detection," affirms Frank van Asch, CTO, RenovaroCube. "With its introduction, we are one step closer to realizing our vision of a world where cancer is detected and treated swiftly, saving countless lives in the process."

RenovaroCube invites interested doctors and scientists from international research institutions, clinical cancer centers and all stakeholders to join in the early research use application of our AI/machine learning platform to advance cancer diagnostics and pave the way for a healthier future.

About Renovaro:

Please see a recent interview with Avram Miller, Member of, and Advisor to, the Board of Directors, former co-founder of Intel Capital and SVP of Business Development for Intel:

https://techbullion.com/avram-miller-talks-about-renovaro-and-its-impact-in-diagnosing-cancers-and-infectious-diseases-with-ai

Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro includes RenovaroBio, with its advanced cell-gene immunotherapy company, and RenovaroCube. RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.

Upon the closing of the previously announced acquisition of Cyclomics (winner of the Health Holland Venture Challenge), RenovaroCube will be capable of performing liquid biopsies using proprietary technologies to identify single cancer DNA molecules in only one vial of blood. In combination with Oxford Nanopore Technology, genetic information can be retrieved over multiple genetic layers to develop the next generation of cancer diagnostics. This will transform cancer care by enabling faster and more accurate diagnosis throughout the patient journey.

https://www.renovarogroup.com

https://www.renovarobio.com

https://www.renovarocube.com

About Cyclomics:
Cyclomics is a Dutch company founded in 2018, winner of the Health Holland Venture Challenge (startup of the year) by scientists of the UMC Utrecht. Its ambition is to transform cancer care by enabling faster and more reliable diagnoses, particularly in the context of cancer recurrence thanks to its proprietary circulating tumor DNA (ctDNA) detection technology.

https://www.cyclomics.com/

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For media inquiries, please contact: karen@renovarocube.com

Source: Renovaro Inc.

https://www.globenewswire.com/newsroom/ti?nf=OTEwODQ5OCM2MjI2Njk4IzIxMjA2Nzk=
https://ml.globenewswire.com/media/OThkZGJkYzMtMDEzYi00YTcxLThhZWEtZDdmMDQ2ZDA4NzdlLTExMzIyNTA=/tiny/Renovaro-Inc.png

Source: Renovaro Inc
👍️ 2 💯 1
jedijazz jedijazz 1 month ago
$RENB Avram Miller Talks About Renovaro And Its Impact In Diagnosing Cancers and Infectious Diseases With AI - https://techbullion.com/avram-miller-talks-about-renovaro-and-its-impact-in-diagnosing-cancers-and-infectious-diseases-with-ai/ Renovaro (Nasdaq: RENB) is a trailblazer in AI-driven early cancer diagnostics and therapeutics #cancer #FDA
@nasdaq
👍️ 2 💥 1 💪 1 💯 1
jedijazz jedijazz 2 months ago
$RENB NEWS: RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership https://finance.yahoo.com/news/renovarocube-acquire-100-ownership-cyclomics-130000419.html
👍️ 2 💪 1 💯 1 😍 1
jedijazz jedijazz 2 months ago
Good morning $RENB.
👍️ 1 💯 1
jedijazz jedijazz 2 months ago
$RENB News: Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board, A Move That Heralds a New Era of Innovation and Progress in its Mission to Reshape Cancer Screening, Diagnosis, and Patient Care
Renovaro Biosciences Inc.
Thu, April 18, 2024 at 8:45 AM EDT
In this article: RENB
+5.41%

LOS ANGELES and AMSTERDAM, April 18, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (Nasdaq: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, announces the distinguished Professor Geert Kazemier, MD, PhD, as the new Chairman of its Scientific Advisory Board. This pivotal move signifies a major leap forward in Renovaro’s quest to redefine cancer diagnosis and treatment through cutting-edge AI and immunotherapy technologies.

Professor Kazemier is the Clinical Director and scientific co-director of the Cancer Center at Amsterdam University Medical Center. The center has an extensive repository of biobank tumor material and liquid biopsies, including an extensive range of data from biomarkers, amongst others, for co-rectal, urogenital, lung, and breast cancers.

Professor Kazemier has made groundbreaking contributions to oncology and surgical research. His depth of experience and trailblazing academic and clinical leadership align perfectly with Renovaro's mission. Professor Kazemier's commitment to medical advancement positions him as an ideal leader to propel Renovaro's Scientific Advisory Board during a transformative era in oncology characterized by the integration of Artificial Intelligence.

Under Professor Kazemier’s direction, Amsterdam University Medical Center’s Cancer Center has launched numerous pioneering research projects, substantially enriching our understanding and treatment of cancer. His drive for innovation and excellence echoes Renovaro’s dedication to advancing early diagnosis, accurate response prediction, effective monitoring, and personalized therapy.

As the Chairman of the Scientific Advisory Board, Professor Kazemier is set to influence Renovaro's research and development trajectory. We believe his expertise and forward-thinking approach will guide Renovaro in refining the company's strategic initiatives, including data acquisition and biomarker selection, to position Renovaro at the forefront of innovation. His leadership will prioritize novel research paths with the power to potentially transform cancer diagnosis, monitoring, and treatment processes.

“We are honored to have Professor Kazemier join our team,” remarked Hon Mark Dybul, MD, CEO of Renovaro. “His extraordinary achievements in medical research and visionary leadership are tremendous assets to Renovaro. With Professor Kazemier guiding our Scientific Advisory Board, we are even more confident in our global mission to revolutionize patient care through regenerative medicine.”

Expressing his excitement, Professor Kazemier shared, “I am enthusiastic about playing a role in the evolution of Renovaro's AI platform, 'the Cube,' having witnessed its growth from inception to its current state. I am excited to further contribute to Renovaro’s groundbreaking efforts to reshape the landscape of cancer care. I believe the Cube’s potential to shift cancer patient care from diagnosis to therapy is extraordinary. I eagerly anticipate collaborating with Renovaro’s gifted team to steer the company's research towards transformative medical innovations.”

With Professor Kazemier's appointment, Renovaro cements its status as an AI/biotech frontrunner, ready to drive significant advancements in medical science and enhance patient outcomes in the fight against cancer.

About Renovaro:

Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro includes Renovaro Biosciences with its advanced cell-gene immunotherapy company and Renovaro Cube. Renovaro Cube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. Renovaro Cube intervenes at a stage where potential therapy can be most effective. Renovaro Cube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.

Upon the closing of the previously announced acquisition of Cyclomics (winner of the Health Holland Venture Challenge), Renovaro Cube will be capable of performing liquid biopsies using proprietary technologies to identify single cancer DNA molecules in only one vial of blood. In combination with Oxford Nanopore Technology, genetic information can be retrieved over multiple genetic layers to develop the next generation of cancer diagnostics. This will transform cancer care by enabling faster and more accurate diagnosis throughout the patient journey.

About Prof. Kazemier
Professor Geert Kazemier, MD, PhD, went to medical school and trained as an oncologic and transplant surgeon at Erasmus University Rotterdam, The Netherlands. After a fellowship in hepatobiliary surgery and transplantation at Universitätsklinikum-Eppendorf in Hamburg, Germany, he became a Consultant Hepatobiliary Surgery and Transplantation at Erasmus Medical Center and was later appointed Program Leader of Liver Transplantation there. In 2012, he was appointed as a full hepatobiliary surgery and transplantation professor at Amsterdam University Medical Center. He is currently the Clinical Director and Scientific co-director of Cancer Center Amsterdam at Amsterdam UMC. In his research, he aims to put fundamental research to work in clinical practice as he focuses on developing biomarkers for pancreatic and bile duct cancer and investigating the added value of Artificial Intelligence in liver tumors.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For media inquiries, please contact: karen@renovarocube.com

Source: Renovaro Inc.
👍️ 2 🤮 1
ProfitScout ProfitScout 2 months ago
$RENB: Top 10 Reasons to Have on your RADAR 
https://twitter.com/JediJazz22/status/1777421007134867796/photo/1
👍️ 1
jedijazz jedijazz 2 months ago
$RENB stock market is rallying $2.90 +5.07% HOD $2.93
👍️ 1 💪 1 💯 1 😍 1
jedijazz jedijazz 2 months ago
$RENB $2.94 +5.38% Continuing bullish momentum this week.
👍️ 1 💪 1 💯 1 😍 1
jedijazz jedijazz 2 months ago
$RENB $2.84 +2.53% Renovaro’s mission is to aim to develop definitive, long-term remission therapies for cancers and infectious diseases. https://renovarobio.com/
👍️ 1 💪 1 💯 1 😍 1
jedijazz jedijazz 2 months ago
$RENB $2.82 GEDiCube’s award winning #AI is developing high-performance biomarker panels for 13 different cancers. GEDi Cube Intl Ltd. a London & Netherlands-based advanced AI company and a wholly owned subsidiary of Renovaro Inc. (NASDAQ: RENB) https://axecapitalusa.com/renb/ $GDHG $NRXP $DIS
👍️ 1 💯 1 😍 1
jedijazz jedijazz 2 months ago
$RENB resilient @ $2.69 0.04 (1.51%) HOD $2.72 #shortsqueeze
👍️ 1 💪 1 😍 1
jedijazz jedijazz 3 months ago
$RENB GEDiCUBE Intl Ltd. A wholly owned subsidiary of NASDAQ: RENB announces it has executed a binding Letter of Intent (LOI) to acquire 75% of Cyclomics Renovaro Biosciences Inc. https://www.einpresswire.com/article/688313019/renovaro-biosciences-inc-collaborates-with-nvidia-partner-gedicube-for-advanced-cancer-diagnosis-nasdaq-renb
👍️ 1 💪 1 💯 1 😍 1
jedijazz jedijazz 3 months ago
$RENB #AI Pioneer GEDiCube/ RenovaroCube and Biotech Innovator Renovaro Biosciences Combine Forces to Accelerate Personalized Medicine https://renovarobio.com/news/ai-pioneer-gedicube-and-biotech-innovator-renovaro-biosciences-combine-forces-to-accelerate-personalized-medicine/
👍️ 1 💪 1 💯 1 😍 1 🚀 1
jedijazz jedijazz 3 months ago
$RENB $3.19 +8.50% closing the week bullish! #shortsqueeze
👍️ 1 💪 1 💯 1
jedijazz jedijazz 3 months ago
$RENB $3.17 open. GEDiCUBE Intl Ltd. A wholly owned subsidiary of NASDAQ: RENB announces it has executed a binding Letter of Intent (LOI) to acquire 75% of Cyclomics Renovaro Biosciences Inc. https://www.einpresswire.com/article/688313019/renovaro-biosciences-inc-collaborates-with-nvidia-partner-gedicube-for-advanced-cancer-diagnosis-nasdaq-renb @ein_news
$GRTX $JANX $ZVSA $ADN $IFBD $PUBM $SRFM $TMDX $HOLO $AKLI $BSGM
👍️ 1 💯 1 😍 1
jedijazz jedijazz 3 months ago
$RENB New HOD $3.05 +1.67% $RENB Great article out summarizing Renovaro Biosciences - Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace
https://ir.renovarogroup.com/news/news-details/2024/Cutting-Edge-AI-Company-GEDiCube-and-Cyclomics-sign-binding-LOI-to-join-forces-and-position-themselves-at-the-forefront-of-the-global-liquid-biopsy-marketplace/default.aspx
👍️ 1 💪 1 💯 1 😍 1
jedijazz jedijazz 3 months ago
$RENB $3.04 HOD $3.13 Renovaro Inc. (NASDAQ:RENB) shares shot up 4% during trading. The company traded as high as $3.13 and last traded at $3.04.
👍️ 1 💪 1 💯 1 😍 1
glenn1919 glenn1919 3 months ago
RENB.........................................https://stockcharts.com/h-sc/ui?s=RENB&p=W&b=5&g=0&id=p86431144783
👍️0
jedijazz jedijazz 3 months ago
$RENB opens higher $2.58 +11.69% #bullish
👍️ 1 💪 1 💯 1 😍 1
jedijazz jedijazz 3 months ago
$RENB $2.50 +.29 +13.12% Weekly Chart is Bullish.
👍️ 1 💪 1 💯 1 😍 1 🚀 1
budfoxfun budfoxfun 3 months ago
$RENB heading for $3.00's soon!
👍️ 2 💪 1 💯 1
jedijazz jedijazz 4 months ago
$RENB $2.38 +8.18% In early trading #TuesdayVibes
👍️ 2 💪 1
budfoxfun budfoxfun 4 months ago
$RENB green in power hour!
👍️ 1
jedijazz jedijazz 4 months ago
$RENB $2.19 +6.07% GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace https://finance.yahoo.com/news/cutting-edge-ai-company-gedicube-142500523.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
👍️ 2 💪 1 💯 1
budfoxfun budfoxfun 4 months ago
Cyclomics has developed a groundbreaking diagnostic method for monitoring early cancer recurrence named “CyclomicsSeq”- a novel ctDNA (circulating tumor DNA is tumor-derived fragmented DNA in the bloodstream that is not associated with cells) detection assay based on Oxford Nanopore sequencing which delivers fast, low-cost, and point-of-care sequencing. In contrast to available ctDNA-based methods, “CyclomicsSeq” ensures that even a single ctDNA molecule in the blood can be detected at very high accuracy. This solution consists of a new diagnostic kit (CyclomicsSeq), which has been licensed to Oxford Nanopore (LON: ONT), an RNA/DNA next-generation sequencing platform company.

$RENB
👍️ 2

Your Recent History

Delayed Upgrade Clock